دورية أكاديمية
Development of a model to predict vancomycin serum concentration during continuous infusion of vancomycin in critically ill pediatric patients.
| العنوان: | Development of a model to predict vancomycin serum concentration during continuous infusion of vancomycin in critically ill pediatric patients. |
|---|---|
| المؤلفون: | Han YJ; Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea., Jang W; Department of Pediatrics, Seoul National University Hospital and College of Medicine, Seoul 03080, Korea., Kim JS; College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea., Kim HJ; Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea., Suh SY; Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea., Cho YS; Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea., Park JD; Department of Pediatrics, Seoul National University Hospital and College of Medicine, Seoul 03080, Korea., Lee B; Department of Pediatrics, Seoul National University Hospital and College of Medicine, Seoul 03080, Korea.; Innovative Medical Technology Research Institute, Seoul National University Hospital, Seoul 03080, Korea. |
| المصدر: | The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology [Korean J Physiol Pharmacol] 2024 Mar 01; Vol. 28 (2), pp. 121-127. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Korean Physiological Society [and] Korean Society of Pharmacology Country of Publication: Korea (South) NLM ID: 9709505 Publication Model: Print Cited Medium: Print ISSN: 1226-4512 (Print) Linking ISSN: 12264512 NLM ISO Abbreviation: Korean J Physiol Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul : Korean Physiological Society [and] Korean Society of Pharmacology, 1997- |
| مستخلص: | Vancomycin is a frequently used antibiotic in intensive care units, and the patient's renal clearance affects the pharmacokinetic characteristics of vancomycin. Several advantages have been reported for vancomycin continuous intravenous infusion, but studies on continuous dosing regimens based on patients' renal clearance are insufficient. The aim of this study was to develop a vancomycin serum concentration prediction model by factoring in a patient's renal clearance. Children admitted to our institution between July 1, 2021, and July 31, 2022 with records of continuous infusion of vancomycin were included in the study. Sex, age, height, weight, vancomycin dose by weight, interval from the start of vancomycin administration to the time of therapeutic drug monitoring sampling, and vancomycin serum concentrations were analyzed with the linear regression analysis of the mixed effect model. Univariable regression analysis was performed using the vancomycin serum concentration as a dependent variable. It showed that vancomycin dose (p < 0.001) and serum creatinine (p = 0.007) were factors that had the most impact on vancomycin serum concentration. Vancomycin serum concentration was affected by vancomycin dose (p < 0.001) and serum creatinine (p = 0.001) with statistical significance, and a multivariable regression model was obtained as follows: Vancomycin serum concentration (mg/l) = -1.296 + 0.281 × vancomycin dose (mg/kg) + 20.458 × serum creatinine (mg/dl) (adjusted coefficient of determination, R 2 = 0.66). This prediction model is expected to contribute to establishing an optimal continuous infusion regimen for vancomycin. |
| References: | Ther Drug Monit. 2016 Oct;38(5):559-66. (PMID: 27631462) Clin Infect Dis. 2011 Feb 1;52(3):285-92. (PMID: 21217178) Paediatr Drugs. 2015 Jun;17(3):245-53. (PMID: 25813682) J Crit Care. 2014 Jun;29(3):351-5. (PMID: 24456810) J Crit Care. 2015 Oct;30(5):1153.e1-6. (PMID: 26239323) Pediatr Crit Care Med. 2018 Jun;19(6):e263-e269. (PMID: 29394210) Crit Care Med. 2014 Mar;42(3):520-7. (PMID: 24201175) Int J Antimicrob Agents. 2016 Jan;47(1):28-35. (PMID: 26655032) J Clin Pharm Ther. 2015 Jun;40(3):259-65. (PMID: 25865426) Clin Pharmacokinet. 2012 Jan 1;51(1):1-13. (PMID: 22149255) Antimicrob Agents Chemother. 2011 Jun;55(6):2704-9. (PMID: 21402850) J Antimicrob Chemother. 2012 Jan;67(1):17-24. (PMID: 22028203) Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):763-8. (PMID: 23271675) J Antimicrob Chemother. 2008 Jul;62(1):168-71. (PMID: 18334494) Antimicrob Agents Chemother. 2016 Jul 22;60(8):4750-6. (PMID: 27216073) Ann Intensive Care. 2011 Jul 19;1(1):26. (PMID: 21906376) CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e6. (PMID: 23835886) Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F418-21. (PMID: 18450803) Am J Health Syst Pharm. 2012 Dec 1;69(23):2066-71. (PMID: 23172265) Antimicrob Agents Chemother. 2009 May;53(5):1863-7. (PMID: 19223642) J Pediatric Infect Dis Soc. 2019 May 11;8(2):174-179. (PMID: 29718415) Pediatr Crit Care Med. 2016 Apr;17(4):e138-45. (PMID: 26890194) Arch Dis Child. 2013 Jun;98(6):478-9. (PMID: 23543265) Eur J Clin Pharmacol. 2017 Nov;73(11):1341-1353. (PMID: 28776198) J Burn Care Res. 2012 Nov-Dec;33(6):e254-62. (PMID: 22878490) Crit Care Med. 2005 Sep;33(9):1983-7. (PMID: 16148469) Clin Pharmacokinet. 2004;43(7):417-40. (PMID: 15139793) Antimicrob Agents Chemother. 2001 Sep;45(9):2460-7. (PMID: 11502515) Int J Antimicrob Agents. 2013 Mar;41(3):261-6. (PMID: 23312601) Burns. 2021 Nov;47(7):1495-1501. (PMID: 34538672) J Assoc Med Microbiol Infect Dis Can. 2021 May 3;6(1):3-9. (PMID: 36340210) Fundam Clin Pharmacol. 2018 Jun;32(3):323-329. (PMID: 29315849) |
| فهرسة مساهمة: | Keywords: Intravenous infusions; Pediatric intensive care units; Pharmacokinetics; Vancomycin |
| تواريخ الأحداث: | Date Created: 20240228 Latest Revision: 20240302 |
| رمز التحديث: | 20240302 |
| مُعرف محوري في PubMed: | PMC10902586 |
| DOI: | 10.4196/kjpp.2024.28.2.121 |
| PMID: | 38414395 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!